


## Growth comparison between patients with rapidly progressing MPS VI and unaffected age-adjusted peers 1,4







Adapted From Quartel, JIMD Rep, 2015.

Abbreviations: MPS VI, mucopolysaccharidosis VI; uGAG, urinary glycosaminoglycans.

**Reference: 1.** Quartel A, Hendriksz CJ, Parini R, Graham S, Lin P, Harmatz P. Growth charts for individuals with mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome). *JIMD*. 2015;18:1-11. doi:10.1007/8904\_2014\_333.

<sup>&</sup>lt;sup>a</sup> For the purpose of this data set, patients with uGAG levels of >200 μg/mg creatinine are considered to have rapidly progressing MPS VI.

<sup>&</sup>lt;sup>b</sup> For the purpose of this data set, patients with uGAG levels of 200 μg/mg creatinine are considered to have rapidly progressing MPS VI.